Study to Evaluate Drug-drug Interactions of Guaifenesin and Hydrocodone Bitartrate
Condition: Healthy Subjects
Intervention: Humibid®; Hydrocodone Bitartrate; Humibid® and Hydrocodone Bitartrate tablet
Intervention description: Humibid® 1200 mg (single extended release) tablet; Hydrocodone Bitartrate (3.33 mg q4h X 3); Humibid® 1200 mg (single extended release) tablet and Hydrocodone bitartrate (3.33 mg q4h X 3)
Intervention MeSH terms: Phenylpropanolamine; Hydrocodone; Guaifenesin; Chlorpheniramine, phenylpropanolamine drug combination
Phase: Phase 1
Study type: Interventional
Primary purpose: Supportive Care
Allocation: Randomized
Intervention model: Crossover Assignment
Masking: None (Open Label)
Enrollment: 24.0
Sex: All
Minimum age: 19 Years
Maximum age: 55 Years
Healthy volunteers: Accepts Healthy Volunteers

Summary:

      Determine and compare the plasma concentrations and safety and tolerability of Guaifenesin
      and hydrocodone bitartrate when they are administered alone or in combination to normal
      healthy male and/or female subjects.
    

Eligibility criteria:

        Inclusion Criteria:

          1. Males and/or females between the ages of 19 and 55 years, inclusive.

          2. Females of childbearing potential were using one of the following acceptable birth
             control methods:

               -  Intrauterine device (IUD) in place for at least 3 months prior to study;

               -  Barrier method (condom or diaphragm) with spermicide for at least 14 days prior
                  to screening through 30 days beyond study completion;

               -  Stable hormonal contraceptive for at least 3 months prior to study through 30
                  days beyond completion of study;

             Abstinence was not an acceptable form of contraception.

             Females of non-childbearing potential were surgically sterile (bilateral tubal
             ligation with surgery at least 6 months prior to study, hysterectomy, or bilateral
             oophorectomy at least 3 months prior to study) or postmenopausal <2 years. An FSH >40
             mIU/mL was obtained and in the record.

          3. Good general health was determined by medical history, physical examination,
             electrocardiogram (ECG), and clinical laboratory measures.

          4. Within 15% of Ideal Body Weight as defined by the 1983 Metropolitan Life chart.

          5. Non-tobacco users, who had not used nicotine or nicotine-containing products for at
             least 1 year.

          6. Able to read, understand, and sign the informed consent after the nature of the study
             had been explained.

          7. Negative finding on tests for Hepatitis B and C antigen as well as HIV and pregnancy
             test (if female).

          8. Negative urine screen for drugs of abuse and alcohol at screening and the first check
             in.

          9. Non-alcohol or drug abuser - for alcohol, defined as history of less then 4 drinks
             daily.

        Exclusion Criteria:

          1. Clinically significant abnormalities detected by medical history, physical, ECG, or
             clinical laboratory findings (as determined by the Principal Investigator). Any
             disease or condition which impacted absorption, distribution, metabolism, or
             elimination of the study drugs.

          2. Females who were pregnant or nursing.

          3. History of hypersensitivity reaction to the study drugs or related compounds, such as
             other opioids.

          4. Receipt of an investigational drug within 1 month prior to study enrollment.

          5. Donation of blood or significant loss of blood within 56 days or plasma within 14 days
             prior study enrollment.

          6. Known or suspected use of illicit drugs (including codeine or hydrocodone, etc.).

          7. The use of any medication on a chronic basis with the exception of oral contraceptives
             for women of childbearing potential. An appropriate drug-free period for prescription
             or over-the-counter (OTC) drugs provided to washout any especially long half-life
             drugs.

          8. Consumption of alcohol within 48 hours prior to each dosing period.

          9. Consumption of grapefruit 14 days prior to dosing and throughout the study.

         10. Hemoglobin value < 12 g/dL. If a subject's hemoglobin dropped below 11.0 g/dL the
             subject was dropped from the study at the Principal Investigator's discretion.